Why did 4506.T stock rise today?

4506.T rose 7.49% on 05 Jan 2026 after recent earnings beats and stronger-than-expected revenue. Higher volume and the stock moving above the 50-day average intensified buying from value and momentum traders.

Is Sumitomo Pharma (4506.T) undervalued?

At PE 5.95 and EPS JPY 389.42, 4506.T looks inexpensive versus many healthcare peers. Valuation appears attractive, but investors should consider debt-to-equity 0.99 and working capital metrics before deciding.

What price targets should investors watch for 4506.T?

Scenario targets: re-rating to PE 10 implies JPY 3894.20, PE 15 implies JPY 5841.30. Short-term model forecasts include monthly JPY 2350.08. These are model-based, not guarantees.

When is the next earnings announcement for 4506.T?

The next scheduled earnings announcement in the full quote data is dated 30 Jan 2026 (UTC). Investors should confirm the company release calendar for exact local timings.

JP Stocks

Sumitomo Pharma (4506.T) up 7.49% on JPX 05 Jan 2026: low PE 5.95 flags value

ByDanny Kontos January 5, 2026January 5, 2026

Sumitomo Pharma Co., Ltd. (4506.T) led Japan’s top gainers on JPX, closing up 7.49% at JPY 2467.00 on 05 Jan 2026 as investors reacted to stronger-than-expected earnings and a clear valuation gap. The 1-day move followed a 172.00 JPY rise on volume 7768900.00, well above intraday levels. The 4506.T stock rally reflects improving revenue beats in 2025 and a low price-to-earnings ratio 5.95 that analysts say points to embedded upside if growth stabilises. Meyka AI’s market tools flagged this move as the healthcare sector outperformed peers today Investing.com and price interest showed on broader data Yahoo Finance.